Innoviva, Inc. Announces Rise in Q3 Earnings

Written by Emily J. Thompson, Senior Investment Analyst

INVA+1.02%

Source: NASDAQ.COM

Updated: Nov 06 2025

0mins

Source: NASDAQ.COM

Earnings Growth: Innoviva, Inc. reported a significant increase in earnings for the third quarter, totaling $89.91 million, or $1.08 per share, compared to $1.21 million, or $0.02 per share, from the previous year.
Revenue Increase: The company's revenue rose by 20.4% to $107.80 million, up from $89.51 million in the same quarter last year.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy INVA?" and start using high-conviction signals backed by rigorous historical data.

Sign up today to access powerful investing tools and make smarter, data-driven decisions.

INVA

$19.75+Infinity%1D

Analyst Views on INVA

Wall Street analysts forecast INVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INVA is 37.33 USD with a low forecast of 31.00 USD and a high forecast of 46.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Analyst Rating

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 19.550

Low

31.00

Averages

37.33

High

46.00

Current: 19.550

Low

31.00

Averages

37.33

High

46.00

H.C. Wainwright

Buy

maintain

$45 -> $46

2025-12-16

Reason

H.C. Wainwright

Price Target

$45 -> $46

AI Analysis

2025-12-16

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Innoviva to $46 from $45 and keeps a Buy rating on the shares. The firm says zoliflodacin was approved on schedule.

Goldman Sachs

Sell

initiated

$17

2025-09-30

Reason

Goldman Sachs

Price Target

$17

2025-09-30

initiated

Sell

Reason

Goldman Sachs initiated coverage of Innoviva with a Sell rating and $17 price target. The stock's recent rally has raised the bar for the company's infectious disease platform platform going forward, the analyst tells investors in a research note. The firm believes Innoviva's 2031 royalty-related patent cliff will start to weigh on the stock's performance in 2026.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for INVA

Unlock Now

About INVA

Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The Company's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for INVA?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy INVA?

Get Started Free